BeiGene decides not to license DKK1 drug, but keeps PD-1 combo trial in gastric cancer
Back in early 2020, BeiGene struck a small, $132 million deal — complete with $3 million in cash and $5 million in equity investment — to test …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
